Intermediate Uveitis 

  • Author: Robert H Janigian Jr, MD; Chief Editor: Hampton Roy Sr, MD   more...
 
Updated: Apr 29, 2011
 

Background

Intermediate uveitis refers to inflammation localized to the vitreous and peripheral retina. Intermediate uveitis was first described in the literature as chronic cyclitis by Fuchs in 1908. According to the Standardization of Uveitis Nomenclature Working Group, the primary site of inflammation is the vitreous and such entities as pars planitis, posterior cyclitis, and hyalitis are encompassed. Intermediate uveitis may be initially associated with the development of a systemic disease, such as multiple sclerosis (MS) or sarcoidosis. As such, intermediate uveitis may be the first expression of autoimmunity in these patients.

Pars planitis is considered a subset of intermediate uveitis and is characterized by the presence of white exudates (snowbanks) over the pars plana and ora serrata or by aggregates of inflammatory cells in the vitreous (snowballs) in the absence of an infectious etiology (eg, Lyme disease) or a systemic disease (eg, sarcoidosis). Some authorities believe that patients with pars planitis have worse vitritis, more severe macular edema, and a guarded prognosis compared to other patients with intermediate uveitis. This primary form accounts for over 50% of patients with intermediate uveitis.

Next

Pathophysiology

There may be an immunogenetic predisposition for the disorder in some cases (see Causes), accounting for family clustering that is seen on occasion, indicating environmental or hereditary associations. The available evidence would suggest an autoimmune mechanism; however, the antigenic stimulus remains elusive.

Previous
Next

Epidemiology

Frequency

United States

Traditionally, the proportion of patients with intermediate uveitis is estimated to be 4-8% of uveitis cases in referral centers. The National Institutes of Health (NIH) reports a higher percentage (15%), which may indicate improved awareness or the nature of the uveitis referral clinic. In the pediatric population, intermediate uveitis can account for up to 25% of uveitis cases.

Mortality/Morbidity

Permanent loss of vision is most commonly seen in patients with chronic cystoid macular edema (CME). Every effort must be made to eradicate CME when present. Other less common causes of visual loss include rhegmatogenous retinal detachment, glaucoma, band keratopathy, cataracts, vitreous hemorrhage, epiretinal membrane, and choroidal neovascularization.

Race

No racial predilection exists for this disease.

Sex

The incidence of intermediate uveitis is equal in men and women.

Age

  • Although intermediate uveitis can develop at any age, it primarily afflicts children and young adults. There is a bimodal distribution with one peak in the second decade and another peak in the third or fourth decade.
  • In the pediatric age group, intermediate uveitis is associated with a worse presenting visual acuity. Poorer outcomes may be related to delayed presentation/diagnosis, the inherent difficulties of immunosuppression in children, or a more aggressive disease.
Previous
Proceed to Clinical Presentation
 
 
Contributor Information and Disclosures
Author

Robert H Janigian Jr, MD  Clinical Assistant Professor, Department of Surgery (Ophthalmology), Brown University Medical School

Robert H Janigian Jr, MD is a member of the following medical societies: American Academy of Ophthalmology, American Society of Retina Specialists, and Rhode Island Medical Society

Disclosure: Nothing to disclose.

Coauthor(s)

Theodoros Filippopoulos, MD  Head of Glaucoma Clinic, Athens Vision Eye Institute; Clinical Lecturer, Department of Ophthalmology, Second Ophthalmology Clinic, University of Athens Medical School, Greece

Theodoros Filippopoulos, MD is a member of the following medical societies: American Academy of Ophthalmology, American Glaucoma Society, American Medical Association, American Society of Cataract and Refractive Surgery, and Association for Research in Vision and Ophthalmology

Disclosure: Nothing to disclose.

Brian A Welcome, MD  Staff Physician, Department of Ophthalmology, Rhode Island Hospital

Brian A Welcome, MD is a member of the following medical societies: American Academy of Ophthalmology, American Glaucoma Society, American Medical Association, and American Society of Cataract and Refractive Surgery

Disclosure: Nothing to disclose.

Specialty Editor Board

John D Sheppard Jr, MD, MMSc  Professor of Ophthalmology, Microbiology and Molecular Biology, Clinical Director, Thomas R Lee Center for Ocular Pharmacology, Ophthalmology Residency Research Program Director, Eastern Virginia Medical School; President, Virginia Eye Consultants

John D Sheppard Jr, MD, MMSc is a member of the following medical societies: American Academy of Ophthalmology, American Society for Microbiology, American Society of Cataract and Refractive Surgery, American Uveitis Society, and Association for Research in Vision and Ophthalmology

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD  Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

R Christopher Walton, MD  Professor, Director of Uveitis and Ocular Inflammatory Disease Service, Department of Ophthalmology, Assistant Dean for Graduate Medical Education, University of Tennessee College of Medicine; Consulting Staff, Regional Medical Center, Memphis Veterans Affairs Medical Center, St Jude Children's Research Hospital

R Christopher Walton, MD is a member of the following medical societies: American Academy of Ophthalmology, American College of Healthcare Executives, American Uveitis Society, Association for Research in Vision and Ophthalmology, and Retina Society

Disclosure: Nothing to disclose.

Lance L Brown, OD, MD  Ophthalmologist, Affiliated With Freeman Hospital and St John's Hospital, Regional Eye Center, Joplin, Missouri

Disclosure: Nothing to disclose.

Chief Editor

Hampton Roy Sr, MD  Associate Clinical Professor, Department of Ophthalmology, University of Arkansas for Medical Sciences

Hampton Roy Sr, MD is a member of the following medical societies: American Academy of Ophthalmology, American College of Surgeons, and Pan-American Association of Ophthalmology

Disclosure: Nothing to disclose.

References

  1. Kimura SJ, Hogan MJ. Chronic Cyclitis. Arch of Ophthalmol. 1964;71:193-201.

  2. Raja SC, Jabs DA, Dunn JP, et al. Pars Planitis: Clinical Features and Class II HLA Associations. Ophthalmology. 1999;106 (3):594-599. [Medline].

  3. Malinowski SM, Pulido JS, Folk JC. Long-term visual outcome and complications associated with pars planitis. Ophthalmology. Jun 1993;100(6):818-24; discussion 825. [Medline].

  4. Henderly DE, Haymond RS, Rao NA, et al. The significance of the pars plana exudate in pars planitis. Am J Ophthalmol. May 15 1987;103(5):669-71. [Medline].

  5. Rodriguez A, Calonge M, Pedroza-Seres M, et al. Referral Patterns of Uveitis in a Tertiary Care Center. Archives of Ophthalmology. 1996;114 (5):593-599. [Medline].

  6. Kaplan HJ. Intermediate Uveitis (Pars Planitis, Chronic Cyclitis)- A Four Step Approach to Treatment. In: Saari KM, ed. Uveitis Update. Amsterdam: Exerpta Medica; 1984:169-172.

  7. Hogewind BF, Zijlstra C, Klevering BJ, et al. Intravitreal triamcinolone for the treatment of refractory macular edema in idiopathic intermediate or posterior uveitis. Eur J Ophthalmol. May-Jun 2008;18(3):429-34. [Medline].

  8. Murphy CC, Greiner K, Plskova J, et al. Cyclosporine vs tacrolimus therapy for posterior and intermediate uveitis. Arch Ophthalmol. May 2005;123(5):634-41. [Medline].

  9. Markomichelakis NN, Theodossiadis PG, Pantelia E, et al. Infliximab for chronic cystoid macular edema associated with uveitis. Am J Ophthalmol. Oct 2004;138(4):648-50. [Medline].

  10. Rajaraman RT, Kimura Y, Li S, et al. Retrospective case review of pediatric patients with uveitis treated with infliximab. Ophthalmology. Feb 2006;113(2):308-14. [Medline].

  11. Devenyi RG, Mieler WF, Lambrou FH, et al. Cryopexy of the vitreous base in the management of peripheral uveitis. Am J Ophthalmol. Aug 15 1988;106(2):135-8. [Medline].

  12. Park SE, Mieler WF, Pulido JS. 2 peripheral scatter photocoagulation for neovascularization associated with pars planitis. Arch Ophthalmol. Oct 1995;113(10):1277-80. [Medline].

  13. Becker M, Davis J. Vitrectomy in the treatment of uveitis. Am J Ophthalmol. Dec 2005;140(6):1096-105. [Medline].

  14. Thorne JE, Daniel E, Jabs DA, et al. Smoking as a risk factor for cystoid macular edema complicating intermediate uveitis. Am J Ophthalmol. May 2008;145(5):841-6. [Medline].

  15. Kalinina Ayuso V, Ten Cate HA, van den Does P, Rothova A, de Boer JH. Young age as a risk factor for complicated course and visual outcome in intermediate uveitis in children. Br J Ophthalmol. May 2011;95(5):646-51. [Medline].

  16. Abu El-Asrar AM, Geboes K. An immunohistochemical study of the 'snowbank' in a case of pars planiti. Ocul Immunol Inflamm. Jun 2002;10(2):117-23. [Medline].

  17. Androudi S, Ahmed M, Fiore T, et al. Combined pars plana vitrectomy and phacoemulsification to restore visual acuity in patients with chronic uveitis. J Cataract Refract Surg. Mar 2005;31(3):472-8. [Medline].

  18. Becker MD, Heiligenhaus A, Hudde T, et al. Interferon as a treatment for uveitis associated with multiple sclerosis. Br J Ophthalmol. Oct 2005;89(10):1254-7. [Medline].

  19. Biswas J, Raghavendran SR, Vijaya R. Intermediate uveitis of pars planitis type in identical twins. Report of a case. Int Ophthalmol. 1998;22(5):275-7. [Medline].

  20. Bloch-Michel E, Nussenblatt RB. International Uveitis Study Group recommendations for the evaluation of intraocular inflammatory disease. Am J Ophthalmol. Feb 15 1987;103(2):234-5. [Medline].

  21. Bonfioli AA, Damico FM, Curi AL, et al. Intermediate uveitis. Semin Ophthalmol. Jul-Sep 2005;20(3):147-54. [Medline].

  22. Bora NS, Bora PS, Tandhasetti MT, et al. Molecular cloning, sequencing, and expression of the 36 kDa protein present in pars planitis. Sequence homology with yeast nucleopore complex protein. Invest Ophthalmol Vis Sci. Aug 1996;37(9):1877-83. [Medline].

  23. Boyd SR, Young S, Lightman S. Immunopathology of the noninfectious posterior and intermediate uveitides. Surv Ophthalmol. Nov-Dec 2001;46(3):209-33. [Medline].

  24. Brockhurst RJ, Schepens CL, Okamura ID. Uveitis II. Peripheral Uveitis: Clinical Descriptions, Complications and Differential Diagnosis. Am J Ophthalmol. 1960;49:1257-1266.

  25. Capone A Jr, Aaberg TM. Intermediate Uveitis. In: Albert, Jacobiec FA, eds. Principles and Practice of Ophthalmology. 1994;Philadelphia: WB Saunders:423-442.

  26. Doro D, Manfre A, Deligianni V, et al. Combined 50- and 20-MHz frequency ultrasound imaging in intermediate uveitis. Am J Ophthalmol. May 2006;141(5):953-5. [Medline].

  27. Duguid IG, Ford RL, Horgan SE, et al. Combined orbital floor betamethasone and depot methylprednisolone in uveitis. Ocul Immunol Inflamm. Feb 2005;13(1):19-24. [Medline].

  28. Ganesh SK, Babu K, Biswas J. Phacoemulsification with intraocular lens implantation in cases of pars planitis. J Cataract Refract Surg. Oct 2004;30(10):2072-6. [Medline].

  29. Guest S, Funkhouser E, Lightman S. Pars planitis: a comparison of childhood onset and adult onset disease. Clin Experiment Ophthalmol. Apr 2001;29(2):81-4. [Medline].

  30. Holland GN. The enigma of pars planitis, revisited. Am J Ophthalmol. Apr 2006;141(4):729-30. [Medline].

  31. Jabs DA, Nussenblatt RB, Rosenbaum JT, et al. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol. Sep 2005;140(3):509-16. [Medline].

  32. Jaffe GJ, Martin D, Callanan D, et al. Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study. Ophthalmology. Jun 2006;113(6):1020-7. [Medline].

  33. Jain R, Ferrante P, Reddy GT, et al. Clinical features and visual outcome of intermediate uveitis in children. Clin Experiment Ophthalmol. Feb 2005;33(1):22-5. [Medline].

  34. Kaplan HJ. Surgical Treatment of Intermediate Uveitis. Developments in Ophthalmology. 1992;23:185-189. [Medline].

  35. Malik AR, Pavesio C. The use of low dose methotrexate in children with chronic anterior and intermediate uveitis. Br J Ophthalmol. Jul 2005;89(7):806-8. [Medline].

  36. Miserocchi E, Baltatzis S, Ekong A, et al. Efficacy and safety of chlorambucil in intractable noninfectious uveitis: the Massachusetts Eye and Ear Infirmary experience. Ophthalmology. Jan 2002;109(1):137-42. [Medline].

  37. Murphy CC, Hughes EH, Frost NA, et al. Quality of life and visual function in patients with intermediate uveitis. Br J Ophthalmol. Sep 2005;89(9):1161-5. [Medline].

  38. Nussenblatt RB, Peterson JS, Foster CS, et al. Initial evaluation of subcutaneous daclizumab treatments for noninfectious uveitis: a multicenter noncomparative interventional case series. Ophthalmology. May 2005;112(5):764-70. [Medline].

  39. Nussenblatt RB, Whitcup SM, Palestine AG. Uveitis: Fundamentals and Clinical Practice. 3rd ed. St. Louis: CV Mosby; 2004:291-300.

  40. Okada AA. Noninfectious uveitis: a scarcity of randomized clinical trials. Arch Ophthalmol. May 2005;123(5):682-3. [Medline].

  41. Potter MJ, Myckatyn SO, Maberley AL, et al. Vitrectomy for pars planitis complicated by vitreous hemorrhage: visual outcome and long-term follow-up. Am J Ophthalmol. Apr 2001;131(4):514-5. [Medline].

  42. Reinthal EK, Volker M, Freudenthaler N, et al. [Optical coherence tomography in the diagnosis and follow-up of patients with uveitic macular edema]. Ophthalmologe. Dec 2004;101(12):1181-8. [Medline].

  43. Smith RE. Pars Planitis. In: Ryan SJ, ed. Retina. Vol. 2. St. Louis: CV Mosby; 1973:637-646.

  44. Smith RE, Godfrey WA, Kimura SJ. Chronic cyclitis. I. Course and visual prognosis. Trans Am Acad Ophthalmol Otolaryngol. Nov-Dec 1973;77(6):OP760-8. [Medline].

  45. Smith RE, Nozik RA. Uveitis: A Clinical Approach to Diagnosis and Management. 2nd ed. Baltimore: Williams and Wilkins; 1989:166-170.

  46. Stanford MR, Vaughan RW, Kondeatis E, et al. Are cytokine gene polymorphisms associated with outcome in patients with idiopathic intermediate uveitis in the United Kingdom?. Br J Ophthalmol. Aug 2005;89(8):1013-6. [Medline].

  47. Stavrou P, Baltatzis S, Letko E, et al. Pars plana vitrectomy in patients with intermediate uveitis. Ocul Immunol Inflamm. Sep 2001;9(3):141-51. [Medline].

  48. Tabbara KF, Al-Kaff AS, Al-Rajhi AA, et al. Heparin Surface-Modified Intraocular Lenses in Patients with Inactive Uveitis or Diabetes. Ophthalmology. 1998;105(5):843-845. [Medline].

  49. Tessler HH, Fraber MD. Intraocular Lens Implantation Versus no Intraocular Lens Implantation in Patients with Chronic Iridocyclitis and Pars Planitis: A Randomized Prospective Study. Ophthalmology. 1993;100 (8):1206-1209. [Medline].

  50. Trittibach P, Koerner F, Sarra GM, et al. Vitrectomy for juvenile uveitis: prognostic factors for the long-term functional outcome. Eye. Feb 2006;20(2):184-90. [Medline].

  51. Tugal-Tutkun I, Havrlikova K, Power WJ, et al. Changing patterns in uveitis of childhood. Ophthalmology. Mar 1996;103(3):375-83. [Medline].

 
Previous
Next
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.